Patient Reported Outcomes Burdens and Experiences - Phase 3 (PROBE-3)

  • End date
    Dec 31, 2026
  • participants needed
  • sponsor
    McMaster University
Updated on 26 May 2022


The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.



The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development.


Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data).

The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used.

At the same time, the research framework will have the potential for:

  • Expanding country participation within existing and new regions.
  • Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries.
  • Using PROBE in new countries
  • Testing the performance of the PROBE questionnaire in new patient populations


Principal Investigator:

  1. Mark Skinner JD, Institute for Policy Advancement Ltd. (US)


2. Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada)

3. Randall Curtis MBA, Factor VIII Computing (US)

4. Neil Frick MS, National Hemophilia Foundation (US)

5. Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US)

6. Declan Noone, Irish Hemophilia Society (Ireland)

7. David Page, Canadian Hemophilia Society (Canada)

8. Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US)

9. Brian O'Mahoney, Irish Hemophilia Society (Ireland)

10. Chatree Chai-Adisaksopha, MD MSc.

Condition Hemophilia, Chronic Disease
Treatment Quality of life measure (survey)
Clinical Study IdentifierNCT03549858
SponsorMcMaster University
Last Modified on26 May 2022


Yes No Not Sure

Inclusion Criteria

PWH will be recruited through national hemophilia patient organizations utilizing their existing membership rosters, social media outlets and meetings / events. The investigators are not proposing a pre-determined method of PWH recruitment. They will utilize the information acquired in the workshop and take-home project to inform best practice in recruitment methodology for the study. The investigators may consider requesting different countries test different PWH recruitment strategies to test reproducibility
In the future, the questionnaire might also be administered to patients with other chronic

Exclusion Criteria

Disease severity and Age bands or age limits (e.g. ≥ Age 18) may be utilized to narrow
the study population
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note